New Zealand markets closed

CLLS Aug 2024 5.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 10:26AM EDT. Market open.
Full screen
Previous close0.0500
Open0.0500
Bid0.0000
Ask0.0000
Strike5.00
Expiry date2024-08-16
Day's range0.0500 - 0.0500
Contract rangeN/A
Volume14
Open interestN/A
  • GlobeNewswire

    Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

    NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing. TALE base editors are a recent and important addition to the gene editing landscape. By design, TALE

  • Zacks

    Cellectis (CLLS) Upgraded to Buy: Here's Why

    Cellectis (CLLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • Zacks

    After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)

    The heavy selling pressure might have exhausted for Cellectis (CLLS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.